Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| International Classification of Diseases | 2 | 2018 | 68 | 1.060 |
Why?
|
| Myocytes, Cardiac | 5 | 2014 | 313 | 0.730 |
Why?
|
| Poverty Areas | 1 | 2020 | 37 | 0.620 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 154 | 0.560 |
Why?
|
| Clinical Coding | 1 | 2018 | 23 | 0.540 |
Why?
|
| Hospitals | 1 | 2020 | 330 | 0.520 |
Why?
|
| Sulfonylurea Receptors | 2 | 2014 | 49 | 0.440 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 238 | 0.390 |
Why?
|
| Embryonic Stem Cells | 3 | 2008 | 85 | 0.350 |
Why?
|
| Heart | 2 | 2014 | 522 | 0.350 |
Why?
|
| Biological Clocks | 2 | 2008 | 76 | 0.330 |
Why?
|
| Algorithms | 4 | 2022 | 1954 | 0.310 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 1516 | 0.270 |
Why?
|
| Gap Junctions | 1 | 2008 | 146 | 0.270 |
Why?
|
| Sinoatrial Node | 1 | 2007 | 12 | 0.270 |
Why?
|
| Pacemaker, Artificial | 1 | 2008 | 109 | 0.260 |
Why?
|
| Cardiomyopathies | 4 | 2014 | 299 | 0.250 |
Why?
|
| Machine Learning | 2 | 2022 | 341 | 0.250 |
Why?
|
| Tissue Engineering | 1 | 2008 | 202 | 0.240 |
Why?
|
| Fibroblasts | 2 | 2010 | 752 | 0.230 |
Why?
|
| KATP Channels | 2 | 2014 | 18 | 0.180 |
Why?
|
| Gene Expression Regulation | 4 | 2014 | 1980 | 0.160 |
Why?
|
| Hospital Mortality | 2 | 2021 | 483 | 0.150 |
Why?
|
| Sodium Channels | 2 | 2012 | 130 | 0.150 |
Why?
|
| Nursing Stations | 1 | 2018 | 1 | 0.140 |
Why?
|
| Environment Design | 1 | 2018 | 9 | 0.140 |
Why?
|
| Critical Illness | 1 | 2021 | 343 | 0.140 |
Why?
|
| Databases, Genetic | 3 | 2014 | 282 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 395 | 0.130 |
Why?
|
| Connexin 43 | 2 | 2008 | 94 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2021 | 454 | 0.130 |
Why?
|
| Mice | 8 | 2014 | 12233 | 0.130 |
Why?
|
| Telemetry | 1 | 2017 | 30 | 0.130 |
Why?
|
| Urinary Catheterization | 1 | 2017 | 40 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 42 | 0.130 |
Why?
|
| Medicare | 1 | 2020 | 455 | 0.120 |
Why?
|
| Penicillins | 1 | 2016 | 24 | 0.120 |
Why?
|
| Drug Hypersensitivity | 1 | 2016 | 39 | 0.120 |
Why?
|
| Hospitalization | 2 | 2022 | 938 | 0.110 |
Why?
|
| Inpatients | 1 | 2018 | 345 | 0.110 |
Why?
|
| Risk Factors | 3 | 2021 | 5912 | 0.110 |
Why?
|
| Length of Stay | 1 | 2018 | 828 | 0.110 |
Why?
|
| Animals, Newborn | 2 | 2014 | 519 | 0.110 |
Why?
|
| Sarcolemma | 1 | 2014 | 30 | 0.100 |
Why?
|
| Genes, p16 | 1 | 2014 | 10 | 0.100 |
Why?
|
| Annexin A6 | 1 | 2014 | 10 | 0.100 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 2014 | 21 | 0.100 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 32 | 0.100 |
Why?
|
| MyoD Protein | 1 | 2014 | 16 | 0.100 |
Why?
|
| Vimentin | 1 | 2014 | 47 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2014 | 33 | 0.100 |
Why?
|
| Humans | 15 | 2022 | 93615 | 0.100 |
Why?
|
| Cell Membrane | 2 | 2014 | 661 | 0.100 |
Why?
|
| Fatty Acids | 1 | 2014 | 145 | 0.100 |
Why?
|
| Animals | 9 | 2014 | 28041 | 0.090 |
Why?
|
| Genome, Human | 2 | 2014 | 823 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 691 | 0.090 |
Why?
|
| Wound Healing | 1 | 2014 | 373 | 0.090 |
Why?
|
| Mice, Transgenic | 3 | 2012 | 1584 | 0.090 |
Why?
|
| Electrocardiography | 2 | 2012 | 494 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 317 | 0.090 |
Why?
|
| Heart Conduction System | 1 | 2012 | 134 | 0.080 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 127 | 0.080 |
Why?
|
| Genetic Variation | 3 | 2014 | 1415 | 0.080 |
Why?
|
| Myocardial Contraction | 2 | 2012 | 188 | 0.080 |
Why?
|
| Lamin Type A | 1 | 2010 | 26 | 0.080 |
Why?
|
| Alternative Splicing | 2 | 2014 | 220 | 0.080 |
Why?
|
| Muscular Dystrophies | 1 | 2010 | 54 | 0.080 |
Why?
|
| United States | 2 | 2021 | 7645 | 0.080 |
Why?
|
| Heart Ventricles | 3 | 2014 | 650 | 0.080 |
Why?
|
| Receptors, Drug | 1 | 2010 | 51 | 0.080 |
Why?
|
| Male | 6 | 2021 | 44578 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 116 | 0.080 |
Why?
|
| Mitochondria | 1 | 2014 | 612 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 3430 | 0.080 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2010 | 140 | 0.080 |
Why?
|
| Software | 1 | 2014 | 670 | 0.080 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2010 | 121 | 0.080 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2012 | 225 | 0.070 |
Why?
|
| Biomedical Engineering | 1 | 2008 | 21 | 0.070 |
Why?
|
| Female | 5 | 2021 | 48779 | 0.070 |
Why?
|
| Transcriptome | 1 | 2014 | 760 | 0.070 |
Why?
|
| Aged | 3 | 2021 | 20469 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2007 | 1243 | 0.070 |
Why?
|
| Electrophysiology | 1 | 2008 | 390 | 0.070 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 1052 | 0.070 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 3 | 2014 | 31 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 474 | 0.070 |
Why?
|
| Chlorofluorocarbons, Methane | 1 | 2006 | 1 | 0.060 |
Why?
|
| Cell Communication | 1 | 2007 | 216 | 0.060 |
Why?
|
| Epinephrine | 1 | 2006 | 92 | 0.060 |
Why?
|
| Kinetics | 1 | 2008 | 1470 | 0.060 |
Why?
|
| Rats | 2 | 2007 | 4042 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1260 | 0.050 |
Why?
|
| Myosin Heavy Chains | 2 | 2014 | 86 | 0.050 |
Why?
|
| Intestinal Diseases | 1 | 1984 | 84 | 0.050 |
Why?
|
| Intracellular Space | 2 | 2014 | 38 | 0.050 |
Why?
|
| Survival Rate | 2 | 2021 | 1950 | 0.040 |
Why?
|
| Intestine, Small | 1 | 1984 | 310 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2008 | 1610 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 2756 | 0.040 |
Why?
|
| Protein Transport | 2 | 2014 | 438 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2021 | 10186 | 0.040 |
Why?
|
| Mutation | 1 | 2010 | 4266 | 0.040 |
Why?
|
| Neoplasms | 1 | 2014 | 3171 | 0.040 |
Why?
|
| Middle Aged | 4 | 2021 | 27621 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1007 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 453 | 0.030 |
Why?
|
| Cost Control | 1 | 2017 | 43 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2022 | 1715 | 0.030 |
Why?
|
| Heart Failure | 1 | 2007 | 1388 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 1702 | 0.030 |
Why?
|
| Adult | 4 | 2018 | 27955 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 185 | 0.030 |
Why?
|
| Child | 2 | 2018 | 7359 | 0.030 |
Why?
|
| LIM Domain Proteins | 1 | 2014 | 24 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 1246 | 0.030 |
Why?
|
| Genes, Modifier | 1 | 2014 | 5 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 3835 | 0.030 |
Why?
|
| Membranes | 1 | 2014 | 35 | 0.030 |
Why?
|
| Abdominal Muscles | 1 | 2014 | 23 | 0.030 |
Why?
|
| Chromosomes, Mammalian | 1 | 2014 | 38 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 3913 | 0.020 |
Why?
|
| Organ Size | 1 | 2014 | 361 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2014 | 221 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 485 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 304 | 0.020 |
Why?
|
| Connectin | 1 | 2012 | 6 | 0.020 |
Why?
|
| Cardiac Myosins | 1 | 2012 | 19 | 0.020 |
Why?
|
| Pedigree | 1 | 2014 | 961 | 0.020 |
Why?
|
| Frameshift Mutation | 1 | 2012 | 50 | 0.020 |
Why?
|
| Sarcomeres | 1 | 2012 | 26 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 84 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2012 | 113 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 1923 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2012 | 129 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 3061 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2012 | 210 | 0.020 |
Why?
|
| Cytoplasmic Vesicles | 1 | 2010 | 6 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 891 | 0.020 |
Why?
|
| Dysferlin | 1 | 2010 | 14 | 0.020 |
Why?
|
| Connexins | 1 | 2012 | 206 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2010 | 111 | 0.020 |
Why?
|
| Myoblasts | 1 | 2010 | 33 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 537 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 300 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 296 | 0.020 |
Why?
|
| Coronary Vasospasm | 1 | 2010 | 7 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 630 | 0.020 |
Why?
|
| Lysosomes | 1 | 2010 | 123 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2012 | 293 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 360 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 702 | 0.020 |
Why?
|
| Binding Sites | 1 | 2012 | 1128 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 435 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 281 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2012 | 660 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2012 | 439 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2010 | 602 | 0.020 |
Why?
|
| Myocardium | 1 | 2010 | 570 | 0.020 |
Why?
|
| Bromochlorofluorocarbons | 1 | 2006 | 1 | 0.020 |
Why?
|
| Hydrocarbons, Halogenated | 1 | 2006 | 2 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2010 | 385 | 0.020 |
Why?
|
| Electric Conductivity | 1 | 2006 | 142 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2484 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 947 | 0.010 |
Why?
|
| Transfection | 1 | 2007 | 878 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2006 | 315 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2828 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2010 | 2121 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2491 | 0.010 |
Why?
|
| Action Potentials | 1 | 2006 | 581 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 6938 | 0.010 |
Why?
|
| Radiography | 1 | 1984 | 790 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 9610 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 2020 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1984 | 494 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 3498 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1984 | 4565 | 0.010 |
Why?
|